ASCO: Summit reached with China lung data but new climb begins to prove global benefit
BioSpace
"King Keytruda's reign continues," analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics' ivonescimab were revealed at the American Society for Clinical Oncology in Chica
pharminent
June 1, 2026 (Last updated: June 1, 2026)
BioSpace
“King Keytruda’s reign continues,” analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics’ ivonescimab were revealed at the American Society for Clinical Oncology in Chica
